Strategic partnerships Clarity is actively expanding manufacturing and supply partnerships, including a large-scale Cu-64 supply agreement with Theragenics and a Commercial Manufacturing Agreement with Nucleus RadioPharma for Cu-64 SAR-bisPSMA, presenting immediate sales opportunities in radiopharmaceutical production, supply chain scaling, and contract manufacturing services.

Clinical expansion A broad clinical program across prostate, breast, neuroendocrine tumors, and neuroblastoma indicates multiple near-term product opportunities and potential co-development or sponsorship deals, especially for imaging agents like Cu-64 SAR-bisPSMA and theranostic copper platforms.

Advancing theranostics Targeted Copper Theranostics (TCT) platform combining copper-64 and copper-67 offers a differentiating value proposition with diagnostic and therapeutic pairings, enabling upsell into integrated diagnostic-therapy packages and collaborating on broader oncology indications.

Funding momentum Recent funding rounds totaling substantial capital alongside ongoing revenue generation position Clarity for rapid clinical and manufacturing scale-up, creating opportunities to engage investors and dual-track BD activities for co-funding trials or regional manufacturing deals.

Leadership and visibility New board leadership with an independent non-executive director and active conference participation (EANM) increase credibility and engagement with key oncology and radiopharma stakeholders, enabling targeted outreach to potential partners, distributors, and CRO/CDMO collaborations.